サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1279742

肉腫治療薬の世界市場規模調査＆予測、治療タイプ別（化学療法、標的療法）、地域別分析、2022-2029年

Global Sarcoma Drugs Market Size study & Forecast, by Treatment Type (Chemotherapy, Targeted Therapy) and Regional Analysis, 2022-2029

出版日
ページ情報
英文
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
肉腫治療薬の世界市場規模調査＆予測、治療タイプ別（化学療法、標的療法）、地域別分析、2022-2029年
出版日: 2023年05月13日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

肉腫は、体のどこにでもできるがんの一種です。

肉腫は、軟部肉腫とも呼ばれ、骨や軟部組織に発生する腫瘍の広いカテゴリーです。軟部肉腫は、他の身体構造を連結し、包み込み、支えている組織にできます。筋肉、脂肪、血管、神経、腱、関節の裏などがこの骨格を構成しています。肉腫の種類は70種類以上あります。肉腫の治療方法は、種類、部位、その他の要因によって異なります。肉腫治療薬が使用できる疾患として、悪性骨腫瘍と軟部肉腫があります。軟部肉腫には、横紋筋肉腫、滑膜細胞肉腫、平滑筋肉腫、皮膚線維肉腫などがあります。化学療法、標的薬物療法、その他の処置は、肉腫治療の一部です。市場成長の主な要因は、軟部肉腫の有病率の上昇、肉腫の新薬の製品承認数の増加、主要な市場関係者による買収、提携、合意、パートナーシップなどの主要戦略の採用の増加で、予測期間中の市場成長をサポートすると予想されています。

さらに、軟部肉腫の有病率の上昇は、肉腫治療薬市場に有利な需要を生み出すと予想されています。例えば、米国がん学会は、国内で新たに12,750例の軟部肉腫が確認され、そのうち7,240例が男性、5,510例が女性であると予測しています。本学会の死亡率の推計によると、2019年に肉腫によって死亡するアメリカ人は5,270人と予測されています。米国では年間100万人に40人程度が肉腫に罹患していると報告されています。さらに、肉腫治療薬の研究開発に対する投資の高まりは、予測期間中に市場に有利な機会を生み出すと予測されています。しかし、肉腫治療薬のコストが高いため、2022年から2029年の予測期間中、市場の成長が阻害されます。

世界の肉腫治療薬市場の調査において考慮された主要地域は、アジア太平洋地域、北米、欧州、中南米、その他の地域です。北米は、主要な市場プレイヤーの存在、研究活動の増加、ヘルスケア分野における技術進歩、軟部肉腫の有病率の増加により、市場シェアにおいて世界の主要な地域となっています。一方、アジア太平洋地域は、予測期間中に最も高い成長率を示すと予想されています。これは、ヘルスケア分野の開拓のための政府機関による支出の増加、がんの有病率の上昇、肉腫治療薬の産業数の増加などの要因により、アジア太平洋地域の肉腫治療薬市場に有利な成長見通しをもたらすと考えられます。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国において、業界の質的・量的な側面を取り入れるよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題など、重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場での潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

  • マーケットスナップショット
  • 世界・セグメント別市場推計・予測、2019年～2029年
    • 肉腫治療薬市場、地域別、2019年-2029年
    • 肉腫治療薬市場：治療タイプ別、2019年～2029年
  • 主な動向
  • 調査手法
  • 調査の前提条件

第2章 肉腫治療薬の世界市場の定義と範囲

  • 本調査の目的
  • 市場の定義と範囲
    • 本調査の対象範囲
    • 産業の進化
  • 調査対象年
  • 通貨換算レート

第3章 世界の肉腫治療薬市場力学

  • 肉腫治療薬市場の影響分析（2019年～2029年）
    • 市場促進要因
      • 軟部組織肉腫の有病率の上昇
      • 肉腫用新薬の製品承認数の増加
    • 市場の課題
      • 肉腫治療薬の高コスト
    • 市場機会
      • 肉腫治療薬の研究開発への投資拡大

第4章 世界の肉腫治療薬市場の産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォースモデルの未来的アプローチ（2019年～2029年）
  • PEST分析
    • 政治的
    • 経済的
    • 社会的
    • 技術的
  • 主な投資機会
  • 主要成功戦略
  • 業界専門家別展望
  • アナリストの結論・提言

第5章 リスクアセスメントCOVID-19の影響

  • COVID-19が業界に与える全体的な影響についてのアセスメント
  • COVID-19以前とCOVID-19以後の市場シナリオ

第6章 肉腫治療薬の世界市場：治療タイプ別

  • 市場スナップショット
  • 肉腫治療薬の世界市場、治療タイプ別、実績 - ポテンシャル分析
  • 肉腫治療薬の世界市場、治療タイプ別、推定・予測2019～2029年
  • 肉腫治療薬市場、サブセグメント別分析
    • 化学療法
    • 標的療法

第7章 肉腫治療薬の世界市場：地域別分析

  • 肉腫治療薬市場、地域別市場スナップショット
  • 北米
    • 米国
      • 治療タイプ別の推定・予測、2019年～2029年
    • カナダ
  • 欧州の肉腫治療薬市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋地域の肉腫治療薬市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカの肉腫治療薬市場スナップショット
    • ブラジル
    • メキシコ
    • その他ラテンアメリカ地域
  • 世界のその他の地域

第8章 競合情報

  • 主な市場戦略
  • 企業プロファイル
    • Baxter Healthcare Corporation
      • 主要情報
      • 概要
      • 財務（データの入手が可能な場合のみ）
      • 製品概要
      • 最近の動向
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company Limited
    • AgonOX, Inc.
    • Eisai Co., Ltd.
    • GlaxoSmithKline, plc.
    • Hoffmann-La Roche AG.
    • Johnson and Johnson
    • MERCK & CO., Inc
    • Novartis AG

第9章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査の特徴
  • 調査の前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Sarcoma Drugs Market, report scope
  • TABLE 2. Global Sarcoma Drugs Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Sarcoma Drugs Market estimates & forecasts by Treatment Type 2019-2029 (USD Billion)
  • TABLE 4. Global Sarcoma Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 5. Global Sarcoma Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Sarcoma Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Sarcoma Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Sarcoma Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Sarcoma Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Sarcoma Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Sarcoma Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Sarcoma Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Sarcoma Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. U.S. Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 16. U.S. Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. Canada Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 18. Canada Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 19. Canada Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. UK Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 21. UK Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 22. UK Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. Germany Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 24. Germany Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 25. Germany Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. France Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 27. France Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 28. France Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. Italy Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 30. Italy Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 31. Italy Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Spain Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 33. Spain Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 34. Spain Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. RoE Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 36. RoE Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 37. RoE Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. China Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 39. China Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 40. China Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. India Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 42. India Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 43. India Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. Japan Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 45. Japan Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 46. Japan Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. South Korea Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 48. South Korea Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 49. South Korea Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. Australia Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 51. Australia Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 52. Australia Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. RoAPAC Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. Brazil Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 57. Brazil Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 58. Brazil Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Mexico Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 60. Mexico Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 61. Mexico Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. RoLA Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 63. RoLA Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 64. RoLA Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. Row Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 66. Row Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 67. Row Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. List of secondary sources, used in the study of global Sarcoma Drugs Market
  • TABLE 69. List of primary sources, used in the study of global Sarcoma Drugs Market
  • TABLE 70. Years considered for the study
  • TABLE 71. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Sarcoma Drugs Market, research methodology
  • FIG 2. Global Sarcoma Drugs Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Sarcoma Drugs Market, key trends 2021
  • FIG 5. Global Sarcoma Drugs Market, growth prospects 2022-2029
  • FIG 6. Global Sarcoma Drugs Market, porters 5 force model
  • FIG 7. Global Sarcoma Drugs Market, pest analysis
  • FIG 8. Global Sarcoma Drugs Market, value chain analysis
  • FIG 9. Global Sarcoma Drugs Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Sarcoma Drugs Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Sarcoma Drugs Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Sarcoma Drugs Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Sarcoma Drugs Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Sarcoma Drugs Market, regional snapshot 2019 & 2029
  • FIG 15. North America Sarcoma Drugs Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Sarcoma Drugs Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Sarcoma Drugs Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Sarcoma Drugs Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Sarcoma Drugs Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Sarcoma Drugs Market is valued approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Sarcoma is a type of cancer that can appear anywhere on the body. Sarcomas, also referred to as soft tissue sarcomas, are a broad category of tumors that develop in the bones and soft tissues. Soft tissue sarcomas form in the tissues that connect, envelop, and support other body structures. The muscle, fat, blood vessels, nerves, tendons, and joint lining make up this framework. There are more than 70 different types of sarcoma. The way that the sarcoma is treated will depend on the type, location, and other factors. Malignant bone tumours and soft tissue sarcoma are two conditions for which sarcoma drugs can be used. Soft tissue sarcomas include rhabdomyosarcoma, synovial cell sarcoma, leiomyosarcoma, and dermatofibrosarcoma. Chemotherapy, targeted medication therapy, and other procedures are part of the sarcoma treatment. The key factor driving the market growth is rise in the prevalence of soft tissue sarcoma, increasing number of product approval for new sarcoma drugs, and growing adoption of key strategies such as acquisition, collaboration, agreement and partnership by key market players that anticipated to support the market growth during forecast period.

Moreover, the rising prevalence of soft tissue sarcoma is anticipated to create the lucrative demand for the sarcoma drugs market. For instance, The American Cancer Society estimates that 12,750 new cases of soft tissue sarcoma will be identified across the country, 7,240 of which will be male and 5,510 of which will be female. According to this society's estimates of mortality, 5,270 Americans are predicted to die by sarcoma in 2019. It has been reported that about 40 people in 1 million have Sarcoma in the United States yearly. Additionally, rising investment for the research and development of sarcoma drugs is anticipated to create the lucrative opportunity for the market during forecast period. However, the high cost of Sarcoma Drugs stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Sarcoma Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the presence of key market players, rising the number of research activities, growing technological advancement in the healthcare sector and increasing the prevalence of soft tissue sarcoma in the region. Whereas, Asia Pacific is also anticipated to exhibit highest growth rate over the forecast period, owing to factors such as increase in expenditure by government organization to develop healthcare sector, rise in prevalence of cancer and growing the number of sarcoma drugs industry would create lucrative growth prospects for the Sarcoma Drugs market across Asia Pacific region.

Major market players included in this report are:

  • Baxter Healthcare Corporation
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company Limited
  • AgonOX, Inc.
  • Eisai Co., Ltd.
  • GlaxoSmithKline, plc.
  • Hoffmann-La Roche AG.
  • Johnson and Johnson
  • MERCK & CO., Inc
  • Novartis AG

Recent Developments in the Market:

  • In 2020, Junshi Biosciences, a worldwide biopharmaceutical company, acquired FDA approval for Orphan Drug name for toripalimab to treat soft tissue sarcoma. This approval is anticipated to help the company offer innovative products and bring in new clients, boosting revenue.

Global Sarcoma Drugs Market Report Scope:

  • Historical Data: 2019-2020-2021
  • Base Year for Estimation: 2021
  • Forecast period: 2022-2029
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Treatment Type, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Treatment Type:

  • Chemotherapy
  • Targeted Therapy

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Sarcoma Drugs Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Sarcoma Drugs Market, by Treatment Type, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Sarcoma Drugs Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Sarcoma Drugs Market Dynamics

  • 3.1. Sarcoma Drugs Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rise in the prevalence of soft tissue sarcoma
      • 3.1.1.2. Increasing number of product approval for new sarcoma drugs
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Sarcoma Drugs
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rising investment for the research and development of sarcoma drugs

Chapter 4. Global Sarcoma Drugs Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Sarcoma Drugs Market, by Treatment Type

  • 6.1. Market Snapshot
  • 6.2. Global Sarcoma Drugs Market by Treatment Type, Performance - Potential Analysis
  • 6.3. Global Sarcoma Drugs Market Estimates & Forecasts by Treatment Type 2019-2029 (USD Billion)
  • 6.4. Sarcoma Drugs Market, Sub Segment Analysis
    • 6.4.1. Chemotherapy
    • 6.4.2. Targeted Therapy

Chapter 7. Global Sarcoma Drugs Market, Regional Analysis

  • 7.1. Sarcoma Drugs Market, Regional Market Snapshot
  • 7.2. North America Sarcoma Drugs Market
    • 7.2.1. U.S. Sarcoma Drugs Market
      • 7.2.1.1. Treatment Type breakdown estimates & forecasts, 2019-2029
    • 7.2.2. Canada Sarcoma Drugs Market
  • 7.3. Europe Sarcoma Drugs Market Snapshot
    • 7.3.1. U.K. Sarcoma Drugs Market
    • 7.3.2. Germany Sarcoma Drugs Market
    • 7.3.3. France Sarcoma Drugs Market
    • 7.3.4. Spain Sarcoma Drugs Market
    • 7.3.5. Italy Sarcoma Drugs Market
    • 7.3.6. Rest of Europe Sarcoma Drugs Market
  • 7.4. Asia-Pacific Sarcoma Drugs Market Snapshot
    • 7.4.1. China Sarcoma Drugs Market
    • 7.4.2. India Sarcoma Drugs Market
    • 7.4.3. Japan Sarcoma Drugs Market
    • 7.4.4. Australia Sarcoma Drugs Market
    • 7.4.5. South Korea Sarcoma Drugs Market
    • 7.4.6. Rest of Asia Pacific Sarcoma Drugs Market
  • 7.5. Latin America Sarcoma Drugs Market Snapshot
    • 7.5.1. Brazil Sarcoma Drugs Market
    • 7.5.2. Mexico Sarcoma Drugs Market
    • 7.5.3. Rest of Latin America Sarcoma Drugs Market
  • 7.6. Rest of The World Sarcoma Drugs Market

Chapter 8. Competitive Intelligence

  • 8.1. Top Market Strategies
  • 8.2. Company Profiles
    • 8.2.1. Baxter Healthcare Corporation
      • 8.2.1.1. Key Information
      • 8.2.1.2. Overview
      • 8.2.1.3. Financial (Subject to Data Availability)
      • 8.2.1.4. Product Summary
      • 8.2.1.5. Recent Developments
    • 8.2.2. Bristol-Myers Squibb Company
    • 8.2.3. Daiichi Sankyo Company Limited
    • 8.2.4. AgonOX, Inc.
    • 8.2.5. Eisai Co., Ltd.
    • 8.2.6. GlaxoSmithKline, plc.
    • 8.2.7. Hoffmann-La Roche AG.
    • 8.2.8. Johnson and Johnson
    • 8.2.9. MERCK & CO., Inc
    • 8.2.10. Novartis AG

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes
  • 9.3. Research Assumption